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Abstract 
Sudden cardiac death (SCD) in a young athlete is rare, but 
catastrophic. Exercise acts as a risk factor for SCD in people with 
cardiovascular disease. A diversity of cardiovascular disorders 
including hypertrophic
  cardiomyopathy, congenital
  coronary 
anomalies, arrhythmogenic right ventricular dysplasia, dilated 
cardiomyopathy, aortic rupture due to Marfan syndrome, myocarditis, 
valvular disease and electrical disorders (Wolff–Parkinson–White 
syndrome, long QT syndrome, Brugada syndrome), as well as 
commotio cordis represent the common causes of SCD in young 
athletes.   
     As the outcome of lethal cardiovascular disorders is not reversible 
except in few cases, effective measures should be addressed to reduce 
the burden of sudden cardiac death in young athletes. Currently, two 
types of recommendations are proposed by American and European 
countries. 
     It seems that there are some special considerations in Asia, entirely 
different from North America or Europe, which warrant more 
comprehensive research on epidemiology and etiology of SCD in young 
Asian athletes by country and evaluation of current national 
preventive strategies and their achievements in decreasing the risk. 
Using these data and considering regional restrictions, an expert group 
will be able to plan a practical and feasible preventive strategy. 
    Asian Journal of Sports Medicine, Volume 2 (Number 1), March 2011, Pages: 1-15 
 
INTRODUCTION 
udden cardiac death (SCD) in an athlete is a rare, 
but tragic event. Various definitions have been 
used for sudden cardiac death by different 
organizations or authors which in turn may affect the 
estimated prevalence among athletic populations
[1-12]. 
American college of cardiology defines SCD as 
‘‘nontraumatic and unexpected sudden death that may 
occur from a cardiac arrest, within 6 hours of a 
previously normal state of health’’
[1]. 
     According  to  the  World  Health  Organization 
definition, SCD refers to an unexpected death within 1 
hour of symptom onset if witnessed or within 24 hours 
of being observed alive and symptom-free if 
unwitnessed
[2]. 
          However, this definition includes many cases of 
well-established acute myocardial infarction, and 
therefore, should not be considered as sudden cardiac 
deaths
[5].  Some other authors define SCD as death 
within 1h of the onset of symptoms in someone without 
a previously recognised cardiovascular abnormality, 
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excluding respiratory, cerebrovascular and drug related 
deaths
[8,9].  
     Sport  related  SCD  was  defined  as  non-traumatic 
SCD during or within 1 hour after moderate- to high-
intensity exercise in a competitive athlete. The 
deceased was considered a competitive athlete if he or 
she did physically demanding sports and took part in 
competitions
[13]. 
EPIDEMIOLOGY 
Exercise acts as a trigger for sudden cardiac death in 
people with cardiovascular disease. The risk for sudden 
death in young athletes with cardiovascular disease is 
2.5 times higher than that in non-athletes. Greater than 
90% of sudden cardiac death occurs during or 
immediately after a training session or competition
[15].  
          The incidence of sudden cardiac death in any 
population including athletes varies depending on 
multiple parameters including sex, age, ethnic group, 
nationality, screening methods to reveal sudden death, 
and attempts to prevent or avert sudden death. It also 
depends upon the definition used and how the 
diagnosis is made
[3].  
          The incidence of SCD in the general population 
(>35 years of age) is estimated to be 1 in 1000 persons 
per year
[15]. In young people (<35 years of age), the 
incidence of all sudden deaths (including non-cardiac 
causes) is 1.5–6.5 per 100 000 persons per year, and 
the incidence of SCD is 0.3–3.6 per 100 000 persons 
per year
[16-21].  
     In US high-school and college athletes (age 12–24 
years), the incidence of SCD has been found to be 
0.5/100 000 participants per year
[20], whereas  the 
incidence was found to be 3.6/100 000 in Italian 
competitive athletes (age 14–35 years)
[21]. According to 
the National Center for Catastrophic Sport Injury 
Research in the USA, the rate of SCD is five times 
higher in male than female high-school and college 
athletes (0.75 vs 0.13 per 100 000 athletes per year)
[20]. 
Moreover, the estimated death rate is twice in college 
athletes (age ranging from 20 to 24 years) compared 
with their high school (age ranging between 12 and 19 
years) counterparts (1.45 vs 0.66 per 100 000 athletes 
per year)
[20]. 
     Similar  studies  on  Scandinavian  people  have 
reported that the incidence of deaths among physically 
active young men were 0.9 and 1.21 per 100 000 
athlete person-years in Norway and Denmark 
respectively
[13,22].  
COMMON CAUSES FOR SPORT 
RELATED SUDDEN CARDIAC DEATH 
A variety of cardiovascular abnormalities represent the 
most
 common causes of sudden death in competitive 
athletes. The specific pathologies
  responsible for 
athletic field catastrophes vary noticeably with regard 
to age. For example, in young athletes (younger
 than 35 
years) the vast majority of sudden deaths are due to
 
underlying cardiovascular abnormalities including 
hypertrophic
  cardiomyopathy, congenital
  coronary 
anomalies and arrhythmogenic right ventricular 
dysplasia (ARVD).
 These deaths occur most commonly 
in team sports such as basketball
 and football, which 
have the highest levels of participation
[8,23,24]. 
          To a lesser extent, other abnormalities including 
dilated cardiomyopathy, aortic rupture in the context of 
Marfan syndrome, myocarditis, valvular disease (aortic 
stenosis, mitral valve prolapse) and electrical disorders 
(Wolff–Parkinson–White syndrome, long QT 
syndrome, Brugada syndrome), as well as commotio 
cordis (malignant arrhythmia due to blunt chest 
trauma) are responsible
[8,10, 25, 26]. In athletes with more 
than 35 years of age that constitute the minority of 
professional athletes, the main cause of death is 
coronary artery disease as in the general population
[24].  
Hypertrophic Cardiomyopathy 
Hypertrophic cardiomyopathy (HCM) is the single 
most common cardiovascular cause of SCD in young 
athletes in the USA, accounting for 35% to 50% of 
cases
[14,24,26,27,28].  
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          It is a primary and familial cardiac disease with 
heterogeneous clinical and morphological expression 
and a diverse clinical course
[8]. The prevalence is about 
0.2%  in the general population
[29], whereas the 
prevalence is estimated to be 0.07% to 0.08% in 
screened athletes
[30,31]. Sudden death from HCM is 
most common in children and young adults (under age 
30), usually in individuals who previously have been 
asymptomatic (or only mildly symptomatic)
[28, 32,33].  
     A remarkable sudden death in Mark Vivien Fue, a 
Cameroon soccer player which occurred during a 
televised international match was attributed to 
ventricular fibrillation due to HCM
[34]. 
          Hence, these mortalities usually occur without 
warning signs and are often the first clinical 
manifestation of the disease, caused by ventricular 
arrhythmia
[26,35,36]. 
          Morphologically, HCM in young people is 
characterised by a spectrum of alterations including 
progressive left ventricular hypertrophy and 
myocardial disarray
[8]. 
      The well documented physical findings of a bifid 
arterial pulse and a loud systolic heart murmur that 
increases in intensity from the Valsalva maneuver or 
standing are only present with left ventricular outflow 
obstruction, which occurs in only 25% of patients with 
HCM
[14,30]. 
     Left ventricular outflow obstruction may also cause 
a decrease in cardiac output and cerebral blood flow, 
leading to syncope. Any athlete who presents with 
unexplained syncope during or after exertion should 
receive a thorough cardiac evaluation. Patients may 
also present with dyspnea on exertion, which is due to 
restricted left ventricular filling or chest pain secondary 
to subendocardial ischemia. The thickened ventricular 
wall and abnormal intramural vasculature limit 
regional coronary blood flow and oxygen delivery to 
the myocardium, resulting in ischemia and chest 
pain
[14, 37]. 
     Sudden cardiac death from HCM is usually caused 
by primary ventricular tachycardia/fibrillation and can 
be the first clinical manifestation of the disease, usually 
in the context of exercise and sports participation
[8,14]. 
The most reliable means for diagnosis of HCM is 2-
dimensional echocardiography. This will demonstrate a 
hypertrophic non-dilated left ventricle in the absence of 
other cardiac or systemic diseases capable of producing 
hypertrophy to the magnitude present
[30,38].  
     However,  the  echocardiographic appearance of 
abnormal ventricular wall thickening may not become 
apparent until adolescence. If HCM is strongly 
suspected, serial echocardiograms should be 
performed. Electrocardiography (ECG) may 
demonstrate evidences of left ventricular hypertrophy, 
showing bizarre patterns with strikingly increased 
voltages, prominent Q waves and/or deeply negative T 
waves
[14]. 
      Clinical diagnosis of HCM is generally based on 
the recognition of the disease phenotype with LV 
hypertrophy
[27,28,32]. In this regard, a maximal LV end-
diastolic wall thickness of 15 mm or more (or on 
occasion, 13 or 14 mm) is the absolute dimension 
generally accepted for the clinical diagnosis of HCM in 
an adult athlete (in children, 2 or more standard 
deviations from the mean relative to body surface are; 
z-score of 2 or more). However, any LV wall thickness 
(including normal) is theoretically compatible with the 
presence of a mutant HCM gene
[1,27,28,32]. 
          Athletes with a probable or unequivocal clinical 
diagnosis of HCM should be excluded from the most 
competitive sports with the possible exception of those 
with low intensity of static and dynamic load. This 
recommendation is independent of age, sex, and 
phenotypic appearance, and does not differ for those 
athletes with or without symptoms, LV outflow 
obstruction, or prior treatment
[1]. 
Congenital Coronary Artery Anomaly 
The second most frequent cause of SCD in young 
athletes is a variety of congenital coronary artery 
anomalies which individually are quite rare, accounting 
for only 12% to 20% of SCD cases
[24,37,39].  
          The most common of these malformations is 
anomalous origin of the left main coronary artery from 
the anterior (right) sinus of Valsalva, with an acute 
angled bend coursing between the pulmonary trunk and 
the anterior aspect of the aorta
[40,41,42]. 
     Most  patients  with  coronary artery anomalies are 
asymptomatic, and may die suddenly as the first 
manifestation of their abnormality. Those who are 
symptomatic rarely complain of typical angina,  
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reporting nonspecific symptoms such as syncope, 
dyspnea on exertion and palpitations
[43,44,45]. The vast 
majority of these symptoms are related to exertion. 
Myocardial ischaemia is precipitated by exercise 
because of critically impaired coronary flow due to an 
abnormal, slit-like ostium of the anomalous coronary 
artery, compression of the anomalous artery between 
the pulmonary artery and ascending aorta, or possibly 
coronary spasm triggered by endothelial 
dysfunction
[45]. 
          Transthoracic echocardiography may be useful in 
diagnosis. However, highly trained ultrasound 
technicians using high-quality imaging systems are 
required for accurate and consistent identification of 
the origin of the coronary arteries
[44]. Coronary 
arteriography is indicated if other studies are not 
diagnostic. Surgery is usually performed when the 
diagnosis is made
[46].   
     Detection  of  coronary  anomalies  of  wrong  sinus 
origin warrants the complete exclusion from 
participating in competitive sports. Three months after 
successful operation, an athlete without ischemia, 
arrhythmia, or dysfunction during maximal exercise 
testing can participate in all sports
[40]. 
Arrhythmogenic Right Ventricular Dysplasia (Arvd) 
ARVD is an inherited myocardial disease that 
predominantly affects the right ventricle and, less 
commonly, the left ventricle
[8,25]. Pathologically, 
ARVD is characterised by progressive death of 
myocardial cells with subsequent fibro-fatty 
replacement, and clinically by ventricular and 
supraventricular arrhythmias resulting in SCD
[47,48]. 
     In patients with ARVD, the risk of SCD is 5.4 times 
higher during competitive sports than during sedentary 
activity
[25]. Triggering mechanisms for arrhythmias 
include increased afterload during exercise and 
hypersensitivity to catecholamines due to damage of 
sympathetic nerve trunks
[8,47,49]. 
     In  each  adolescent  or young individual with 
palpitations, syncope, aborted sudden death or 
ventricular tachycardia (VT) of left bundle branch 
block morphology, ARVD should be suspected
[8,49]. 
ECG changes such as T wave inversion in V1–V3 or 
premature ventricular complexes of left bundle branch 
block morphology should also arouse suspicion of 
ARVD, even in asymptomatic individuals
[49]. The 
routine assessment of patients with suspected ARVD 
include clinical and family history, physical 
examination, chest radiography, 12-lead ECG, 24-hour 
ambulatory ECG, signal-averaged ECG, stress test, and 
two-dimensional echocardiography
[49,50]. Due to limited 
ability of ECG and echocardiography to differentiate 
ARVD from benign physiological changes, magnetic 
resonance imaging may offer increased sensitivity for 
this diagnosis 
[14,51]. Athletes with probable or definite 
diagnosis of ARVD should be excluded from most 
competitive sports, with the possible exception of those 
of low static and dynamic intensity
[1]. 
Marfan Syndrome 
Marfan syndrome is an autosomal dominant genetic 
disease with variable penetrance, mostly caused by a 
mutation in the fibrillin-1 gene on chromosome 15. It 
has an increased risk for sudden death due to aortic 
dissection
[14,52,53]. It is characterized clinically by a 
diverse constellation of abnormalities variable in 
severity and involving primarily the ocular, skeletal, 
and cardiovascular organ systems
[1,54].  
            The disease has an estimated incidence of 1 in 
5000-7000 and has been shown to be more common in 
taller athletes such as basketball and volleyball players 
because tallness is one of the phenotypic expressions of 
the syndrome
[52,55,56]. 
     Diagnosis is made according to the Ghent nosology 
if major criteria are present in two organ systems and a 
third is involved, or when there is a family history of 
Marfan syndrome
[1,54]. Skeletal abnormalities include 
arm span to height ratio greater than 1.05, tall stature, 
arachnodactyly, hyperextensibility and ligamentous 
laxity, scoliosis, and chest wall deformity (pectus 
excavatum or carinatum), in addition to ectopia lentis 
(lens dislocation). 
     Cardiovascular  manifestations  that  impact  on 
prognosis consist of progressive dilatation of the aortic 
root or descending aorta which are predisposed to 
dissection and rupture
[57]; and mitral valve prolapse 
with associated mitral regurgitation or LV systolic 
dysfunction, which may occasionally be predisposed to 
ventricular tachyarrhythmias and sudden death
[58].  
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          Echocardiography can be used to measure and 
monitor the degree of aortic root dilation
[14,53]. The risk 
for aortic rupture is usually linked to marked 
enlargement of the aorta (transverse dimension greater 
than 50 mm). However, dissection can also occur with 
a normal (or near-normal) aortic root dimension
[1,58]. 
Weightlifting has been specifically associated with 
aortic dissection in athletes. The incidence of aortic 
dissection appears to decrease with earlier prophylactic 
surgical aortic root reconstruction and beta-blocker 
therapy
[1]. 
     Athletes with Marfan syndrome can participate in 
low and moderate static/low dynamic competitive 
sports if they do not  have any of the aortic root 
dilatation or moderate-to-severe mitral regurgitation or 
family history of dissection or sudden death in a 
Marfan relative. 
          It is recommended, however, that these athletes 
have an echocardiographic measurement of aortic root 
dimension repeated every six months for close 
surveillance of aortic enlargement
[1,55]. 
Myocarditis 
Myocarditis is an inflammatory disease associated with 
cardiac dysfunction and it is diagnosed by established 
histological, immunological, and immunohistochemical 
criteria’’. It is characterized by the histologic evidence 
of inflammatory infiltration associated with myocyte 
degeneration and necrosis of non-ischemic origin
[59]. 
Viral infection is the most common cause of 
myocarditis, with coxsackie B virus implicated in 50% 
of cases
[39,51,60]. 
          Myocarditis increases the risk for sudden death, 
which may occur during both active and healing phases 
of the illness
[51] and accounts for 3–7% of SCDs related 
to sports
[8,20,21,26]. Myocarditis may be clinically silent 
until sudden death occurs, or it may present with 
dyspnea, fatigue, exercise intolerance, palpitations, 
syncope or presyncope, or symptoms of congestive 
heart failure such as orthopnea
[39,60].  
          The clinical evaluation of patients with suspected 
myocarditis includes a personal and family history 
(especially the evidence of fever and flu-like illness, or 
previous viral infection), physical examination, 12-lead 
ECG, and echocardiography
[59,61]. The ECG changes 
include frequent, complex ventricular or supra-
ventricular arrhythmias, ST-T segment depression, T-
wave inversion, and left bundle branch or 
atrioventricular blocks
[61]. Additional testing (such as 
24-hour ECG monitoring) may be required according 
to the specific case
[61]. 
          Athletes with a clinical diagnosis of myocarditis 
should be temporarily excluded from competitive and 
leisure time sport activity. This recommendation is 
independent of age, gender, presenting symptoms and 
selected treatments. After resolution of disease (at least 
6 months after the onset of the disease), clinical 
reassessment is indicated before the athlete returns to a 
competitive sport lifestyle. Furthermore, pre-
participation evaluation should be performed every 6 
months during the follow-up
[1,59]. 
Wolff–Parkinson–White syndrome (WPW) 
Wolff–Parkinson–White syndrome is defined as the 
presence of paroxysmal arrhythmias in a patient with 
ventricular pre-excitation due to an accessory 
pathway
[8,62]. The prevalence of pre-excitation in 
athletes is 0.1–0.3%, similar to that of the general 
population
[63]. Most patients with pre-excitation are 
asymptomatic, but when symptoms do occur, they are 
usually derived from tachyarrhythmias such as atrial or 
ventricular fibrillation
[62,64]. 
     Required studies consist of 12-lead ECG, exercise 
test and echocardiography to exclude associated 
cardiovascular disorders. In some cases, a 24-h ECG 
holter monitoring during athletic activity may be 
indicated. Electrophysiologic studies are indicated in 
athletes with symptoms of impaired consciousness, 
long-term palpitations, or rapid rates in whom an 
ablation procedure is indicated. 
     In  asymptomatic  athletes  with  no  history  of 
palpitations or tachycardia and no evidence of 
structural cardiac abnormalities, further assessment 
may not be required. However, the optimal 
management for these athletes is not verified
[65,66]. 
Among individuals with multiple accessory pathways 
or ventricular rates exceeding 240 beats/min, catheter 
ablation of the accessory pathway should be considered 
[65,67]. For those athletes with a history of palpitations, 
syncope or near syncope, further assessment is   
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mandatory
[64]. 
Congenital long QT syndrome 
The term congenital long QT syndrome (LQTS) 
includes a constellation of inherited disorders caused 
by cardiac ion channel mutations, which produce 
prolonged ventricular repolarization and a tendency to 
polymorphic ventricular tachycardia
[8,68,69,70]. LQTS 
may manifest as palpitation, presyncope, syncope, 
seizure, cardiac arrest and/or SCD in young individuals 
and is often associated with exercise
[24,68, 70]. 
     The QT interval is typically measured in lead II of a 
12-lead ECG and corrected for rate by using Bazett’s 
formula (QTc = QT/√RR). LQTS is defined as a 
corrected QT interval >440 ms in men and >460 ms in 
women
[68,71],  but intervals of >470 ms and >480 ms 
have also been suggested
[72] indicating the lack of well-
defined optimal cut-off value. Extreme QT 
prolongation (usually 500 ms) predisposes cases to 
torsade de pointes and ventricular fibrillation
[73]. 
            The incidence of cases of SCD due to LQTS in 
young athletes is estimated to be from 0.5% to 8%
[6,21, 
26]. Guidelines are more restrictive and specific for 
competitive compared with recreational sports. 
According to the 36th Bethesda conference, athletes 
who have suffered a cardiac arrest and/or a syncopal 
episode because of LQTS should be excluded from 
participation in competitive sports, except those sports 
with low dynamic and static component (golf, as well 
as billiards, bowling, cricket, curling, and riflery)
[74].  
     Asymptomatic  athletes  with  definite  QT 
prolongation in their surface ECG (>470 ms in males, 
>480 ms in females) should also be disqualified from 
all but class IA competitive sports
[64]. In contrast to the 
Bethesda conference, the European conservative 
approach excludes any individual with LQTS from all 
competitive sports participation
[73]. 
Brugada Syndrome 
This is an autosomal dominant cardiac sodium 
channelopathy
[8,68], which clinically presents with 
syncope or less commonly with ventricular fibrillation 
leading to SCD
[73]. Although the disease is recognized 
worldwide, the prevalence seems much higher in some 
areas, especially in Southeast Asia. Prevalence ranging 
from 5 to 66 per 10 000 has been reported
[76]. 
     Electrocardiographically, it is characterized by 
accentuated J wave primarily in leads V1 through V3 
with ST-segment elevation, often followed by a 
negative T-wave and an R prime which is unrelated to 
ischemia, electrolyte disturbances, or obvious structural 
heart disease
[76,77,78].  
     The accentuated J wave simulates an R' and gives 
the appearance of right bundle branch block. The R' in 
Brugada syndrome is thought to be due to early 
repolarisation of the right ventricular epicardium rather 
than the right bundle branch block
[79]. 
     Hyperthermia can potentially uncover the Brugada 
ECG pattern in patients with Brugada syndrome, who 
can then display fever-induced polymorphic ventricular 
arrhythmia. Death often occurs with mild activity or 
during sleep. Although an obvious relation between 
exercise and sudden death has not been recognized, and 
because of the potential effect of hyperthermia, 
restriction to participation in sports with low static and 
dynamic intensity seems advisable
[64]. 
Commotio Cordis  
Commotio cordis is a primary arrhythmic event that 
occurs when the mechanical energy generated by a 
blow is confined to a small area of the precordium 
(particularly at or near the center of the cardiac 
silhouette) and profoundly alters the electrical stability 
of the myocardium, resulting in ventricular fibrillation 
[80,81,82]. 
     About 50% of commotio cordis events have been  
reported in young competitive athletes (mostly those 
between 11 and 20 years of age) participating in a 
variety of organized amateur sports -typically baseball, 
softball, ice hockey, football, or lacrosse- who receive 
a blow to the chest that is usually (but not always) 
delivered by a projectile used to play the game. It may 
also result from physical contact between competitors 
[80,82, 83,84].  
          The timing of the blow is also important, which 
must occur during an electrically vulnerable period 
within a narrow window of 10 to 20 msec on the 
upstroke of the T wave, just before its peak (accounting 
for only 1% of the cardiac cycle)
[82,85].   
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          The survival rate is poor, as low as about 15%, 
likely due to lack of early recognition and the failure to 
initiate timely aggressive resuscitation. Survival is 
most likely to occur with the institution of 
cardiopulmonary resuscitation and defibrillation within 
3 minutes of the incidental event
[80,82]. 
ILLICIT DRUGS AND SCD 
Some prohibited substances, especially anabolic 
steroids, stimulants and peptide hormones, may cause a 
wide range of cardiac arrhythmias (focal or reentry 
type, supraventricular and/or ventricular), even in 
healthy subjects with no previous history of cardiac 
diseases. Therefore, physicians should always take into 
consideration the possibility of illicit drug abuse as the 
cause of lethal arrythmia, especially if no signs of 
cardiac diseases are present
[86,87,88]. 
PREVENTIVE STRATEGIES 
As common sence indicates “An ounce of prevention is 
worth a pound of cure” and because the oucome of 
lethal cardiovascular disoders is not reversible except 
in few cases, effective and efficient measures should be 
addressed to reduce the burden of sudden cardiac death 
in young athletes. Nowadays two types of 
recommendations are proposed, each is propagated by 
American and European countries. 
AMERICAN APPROACH 
In 1996, the American Heart Association (AHA) 
released a scientific statement advocating universal 
cardiovascular preparticipation screening for young 
athletes in an attempt to identify those who are 
vulnerable to cardiovascular events
[23]. The 
recommendations included a 12-element complete 
history and physical examination (including blood 
pressure measurement) before competitive sports 
(Table 1) and reserved non-invasive testing such as a 
12-lead ECG, echocardiography, exercise testing, and 
cardiovascular consultation for athletes with detected 
abnormality
[89,90]. 
     The  recommendations  included  cardiovascular 
screening every 2 years with an abbreviated 
examination in intervening years. The committee 
recommended a national standard for preparticipation 
cardiovascular medical evaluation and education of all 
healthcare providers who screen athletes. Routine 
diagnostic tests (ie, ECG) as part of the screening were 
excluded primarily for cost-efficacy considerations
[90]. 
     In  2007  update,  the  AHA  12-element  recom-
mendations remained unchanged and did not include 
universal 12-lead ECG recordings as part of 
preparticipation history and physical examination, 
unless the athlete fails the 12-element examination. 
These recommendations have also been endorsed by 
American College of Cardiology Foundation
[89]. 
However, it seems that elderly competitive athletes 
should be assessed with more caution
[89,91]. 
          These recommendations rely greatly on cost 
efficacy studies in USA. For example, AHA experts 
have assumed that in USA, about 10 million high 
school and middle school athletes would be eligible for 
annual screening with costs (based on Center for 
Medicare Services–approved reimbursements) of $25 
for each personal and family history and physical 
examination and $50 for each ECG. Consequently, the 
expense for the primary evaluations would be $750 
million. In addition, positive results in history, physical 
examination, or ECG could be expected to affect 
approximately 15% of the 10 million screened athletes 
(1.5 million)
[30,89,92]. This would justify a non-invasive 
evaluation including another visit by cardiologist 
($100) and 2-dimensional echocardiography ($400).   
     This  secondary  evaluation  would  add  about  $750 
million to the cost of the program each year, which 
would make the minimum annual total of $1.5 billion. 
However, this analysis does not consider all the 
substantial administrative resources and costs 
necessary to operate a program of this magnitude and 
other  medical  expenses  in  selected athletes suspected 
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Table 1: The 12-Element AHA Recommendations for Preparticipation Cardiovascular Screening of Competitive Athletes 
[89] 
Medical history* 
Personal history 
1. Exertional chest pain/discomfort 
2. Unexplained syncope/near syncope† 
3. Excessive exertional and unexplained dyspnea/fatigue associated with exercise  
4. Prior recognition of a heart murmur 
5. Elevated systemic blood pressure 
Family history 
6. Premature death (sudden and unexpected or otherwise) before 50 y of age resulting from heart disease in 1 relative 
7. Disability from heart disease in a close relative _50 y of age 
8. Specific knowledge of certain cardiac conditions in family members: hypertrophic or dilated cardiomyopathy, long-QT 
syndrome or other ion channelopathies, Marfan syndrome, or clinically important arrhythmias 
Physical examination 
9. Heart murmur‡ 
10. Femoral pulses to exclude aortic coarctation 
11. Physical stigmata of Marfan syndrome 
12. Brachial artery blood pressure (sitting position)§ 
*Parental verification is recommended for high school and middle school athletes. 
†Judged not to be neurocardiogenic (vasovagal); of particular concern when related to exertion. 
‡Auscultation should be performed in both supine and standing positions (or with Valsalva maneuver), specifically to identify murmurs of 
dynamic left ventricular outflow tract obstruction. 
§Preferably taken in both arms. 
of having cardiovascular disease. It would add another 
$500 million to the overall cost, for an annual total of 
$2.0 billion. 
     By using the known prevalence of diseases such as 
HCM, ARVD, and ion channelopathies in the general 
population (conservatively 1:1000), it can be supposed 
that ≈10 000 athletes (of the 10 million) would harbor 
these latent cardiac diseases that are eventually 
detectable by screening with ECG
[89]. 
     Of these 10 000 athletes, around 9000 are likely to 
have an abnormal ECG pattern that would raise 
suspicion of cardiac disease during the screening 
process. Given the theoretical cost of a mass 
cardiovascular screening program of $2 billion per 
year, the dollar expenditure linked to detecting each 
athlete with the suspected relevant cardiac diseases 
would be $330 000. With this assumption that about 
10% of these 9000 athletes with cardiac disease (900) 
would harbor evidence of increased risk for sudden 
death
[93], the cost of preventing each theoretical death 
would be $3.3 million
[89].  According to these 
calculations, experts concern the practicality and 
feasibility of establishing a continuous annual national 
program for many years at a cost of approximately $2 
billion per year
[89]. 
EUROPEAN APPROACH 
The European Society of Cardiology (ESC) and the 
International Olympic Committee (IOC) screening 
questionnaires serve an aim similar to that of the 12-
element AHA questionnaire, although they include 
more questions and the content is slightly different 
(Table 2)
[90,94]. However, the prescreening strategy of 
the ESC and IOC is quite different and universal 12-
lead rest ECG is recommended for athletes <35 years, 
leading to a significant controversy between the 
American and European positions on the need for 
routine ECG recording
[95]. 
     The IOC-ESC consensus relied mainly on the 25-
year Italian experience of systematic preparticipation 
screening  of  competitive  athletes.  In 1982, the Italian 
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Table 2: Recommended assessment for all participants at the beginning of competitive activities until 35 years of age (ESC & IOC)
[94] 
Medical History 
Personal History: 
Have you ever fainted or passed out when exercising? 
Do you ever have chest tightness? 
Does running ever cause chest tightness? 
Have you ever had chest tightness, cough, or wheezing that made it difficult for you to perform sports? 
Have you ever been treated/hospitalized for asthma? 
Have you ever had a seizure? 
Have you ever been told that you have epilepsy? 
Have you ever been told to give up sports because of health problems? 
Have you ever been told that you have high blood pressure? 
Have you ever been told that you have high cholesterol? 
Do you have trouble breathing or do you cough during or after activity? 
Have you ever been dizzy during or after exercise? 
Have you ever had chest pain during or after exercise? 
Do you have or have you ever had racing of your heart or skipped heartbeats? 
Do you get tired more quickly than your friends during exercise? 
Have you ever been told that you have a heart murmur? 
Have you ever been told that you have a heart arrhythmia? 
Do you have any other history of heart problems? 
Have you had a severe viral infection (e.g., myocarditis or mononucleosis) within the last month? 
Have you ever been told that you had rheumatic fever? 
Do you have any allergies? 
Are you taking any medications at the present time? 
Have you routinely taken any medication in the past 2 years? 
Family history: 
Has anyone in your family with less than 50 years of age:  
Died suddenly and unexpectedly? 
Been treated for recurrent fainting? 
Had unexplained seizure problems? 
Had unexplained drowning while swimming? 
Had unexplained car accident? 
Had heart transplantation? 
Had pacemaker or defibrillator implanted? 
Been treated for irregular heart beat? 
Had heart surgery? 
Has anyone in your family experienced sudden infant death (cot 
death)? 
Has anyone in your family been told they have Marfan syndrome? 
Physical examination 
General 
Radial and femoral pulses 
Marfan stigmata 
Cardiac auscultation 
Rate/rhythm 
Murmur: systolic/diastolic 
Systolic click 
Blood pressure 
Diagnostic tests 
12-lead resting ECG (after the onset of puberty) 
From the ESC and the IOC Meeting on Sudden Cardiovascular Death in Sport, Lausanne, Switzerland, December 9 to 10, 
2004; Lausanne recommendations adopted. 
 
  ESC: European Society of Cardiology/ IOC: International Olympic Committee / ECG: Electrocardiography  
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government passed a law to insist on preparticipation 
evaluation including at least a general physical 
examination, a 12-lead ECG, and submaximal exercise 
test for all athletes participating in organized 
competitive athletic events and that the screening 
protocol should be conducted annually
[96]. 
     Based on Italian law, it is the responsibility of the 
physician to reveal, with a reasonable degree of 
medical certainty, whether an athlete is free of 
potentially lethal cardiovascular abnormalities during 
athletic activities. In 2006, a report of Italian 
experience using the screening process showed that the 
annual incidence of sudden cardiac death in young 
athletes (12-35 years old) decreased from 3.6 deaths 
per 100 000 person-years in 1979 to 1981 to 0.4 deaths 
per 100 000 person-years in 2003 to 2004, an 89% 
reduction. However, no change occurred in the 
mortality rates among the unscreened non-athletic 
population
[21]. In this report, 9% of screened athletes 
required additional cardiovascular testing, and 2% were 
ultimately prohibited from athletic participation. 
     The  significant  reduction  in  mortality  with 
implementation of more aggressive screening may lead 
to the conclusion that this screening approach should 
be applied universally in all countries. However, there 
may be some limitations in this report
[97]. Indeed, ECG 
may bear considerable advantages. Certain ECG 
findings are characteristic in HCM
[30,98,99] and it is 
stated that the ECG would be abnormal in 90-95% of 
these patients
[28,90].  In addition, some authors have 
reported that an abnormal ECG is an early marker that 
may precede the appearance of left ventricular 
hypertrophy on the echocardiogram and 
symptoms
[100,101]. In Italian preparticipation study, the 
ECG had a 77% greater power to detect HCM than the 
history and physical examination alone
[30]. 
     Among the other cases of SCA in this age group, 
80% of patients with arrhythmogenic right ventricular 
dysplasia have ECG abnormalities, as do high 
proportions of patients with long-QT and Brugada 
syndromes and dilated cardiomyopathy
[98,102-104]. 
However, other conditions associated with sudden 
death during exercise such as Marfan syndrome, 
coronary artery anomalies, or catecholamine-induced 
ventricular tachycardia might not be detected with a 
resting ECG
[90]. 
     Proponents of Italian approach believe that all of the 
reports on the cost-effectiveness of ECG studies, 
whether in Japan, Italy, or the United States, have 
shown a cost per year of life saved well below the $50 
000, figure that is used in public health policy 
discussions
[98]. Of course, preventive strategies of SCD 
in athletes should be programmed largely by region-
specific financial, political, and cultural factors
[105]. 
SPECIAL CONSIDERATIONS IN ASIA 
It seems that there are some special considerations in 
Asia, quite different from North America or Europe, 
which necessitates more comprehensive research on 
epidemiology and etiology of SCD in young Asian 
athletes by country and assessment of current national 
preventive strategies and their success to reduce the 
risk
[106]. Of course, selection of the preferred method 
for preparticipation evaluation of competitive athletes 
should keep these valuable data in consideration and 
modifications should be applied. 
There are some of these considerations:  
1-  Asia is the world's largest and most populous 
continent. It hosts 60% of the world's current 
human population with approximately 4 billion 
people
[107]. Furthermore, the population is growing 
exponentially especially in developing countries of 
Asia
[108]. For this reason, more young athletes exist 
in these countries in comparison with North 
American and European countries. 
2-  A significant incongruity exists between Asian 
countries regarding economic, cultural and health 
parameters. For example, some of Asian countries 
lie in the top of the world’s gross domestic product 
(GDP) ranking and others in the bottom of the 
above mentioned rankings
[109]. Hence, the economic 
burden of screening methods in competitive athletes 
would have completely diverse meanings. 
3-  Popular sports in different countries of Asia are 
quite different. Some of these popular sports such as 
Karate, Taekwondo, Judo, Kabedi, Free-style 
Wrestling, and Cricket, some of which originated in 
Asia, are among combat sport disciplines which  
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may bear the potential risk for commotio cordis as a 
cause of SCD
[80-85]. 
4-  Due to diverse ethnic origins
[110], the epidemiology 
of the most prevalent cause of sudden death may be 
different in comparison with USA or Europe. For 
example, ARVD has reported to be the most 
common cause of sudden cardiac death in young 
people (42% of cases) in an area of southeastern 
Korea
[111]. In other studies from Japan and southern 
Iran, the frequency of a Brugada-type ECG pattern 
is cited to be higher than some European 
countries
[112-114]. On the other hand, the data 
regarding the epidemiology and pathologic causes 
of SCD are unfortunately scarce, especially in 
deprived developing countries. 
5-  The cost of medical services including medical visit 
by general physician or cardiologist, ECG and 
echocardiography may be quite different in 
comparison with European and American countries 
as well as between Asian countries. For example, 
based  on  the  rules  of  medical council  of Iran for 
Medicare Services, the costs for visit of general 
physician, cardiologist, ECG and  2-dimensional 
echocardiography are $7, $12, $4 and $30 
respectively which are much lower compared with 
medical costs both in American and european 
countries
[30,89,92, 98]. 
6-  The coverage of national health insurance services 
may be completely different in different parts of 
Asia.  
     According to these considerations, it seems prudent 
to encourage and support epidemiological studies 
regarding incidence and etiology of SCD in different 
countries of Asia and establish an efficient data registry 
and report system for SCD cases among young athletes 
based on a single accepted definition and well defined 
postmortem studies. It seems that intimate international 
collaboration is necessary for inclusion of such a 
registration system and integrated approach in the 
process of reporting sudden deaths in Asia region.  
          Using these data and considering regional 
restrictions, an expert group from all parts of Asia as 
well as recognized American and European experts 
will be able to plan a practical and feasible preventive 
strategy and design a screening evaluation program 
compatible with special needs and limitations of 
different countries in Asia.   
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